期刊文献+

替吉奥联合三维适形放疗对胰腺癌细胞生物学的影响

Effect of S-1 Combined with Three-dimensional Conformal Radiotherapy on Biological Behavior of Pancreatic Cancer Cells
原文传递
导出
摘要 目的:探究替吉奥复方制剂联合三维适形放射疗法对胰腺癌细胞生物学的影响及安全性评价。方法:培养PANC-1人胰腺癌细胞,构建PANC-1胰腺癌裸鼠异位肿瘤模型并随机进行分组。观察替吉奥联合三维适形放疗对胰腺癌肿瘤细胞生长的抑制作用,记录荷瘤裸鼠的肿瘤体积以及生存期。同时观察联合治疗所产生的副作用。结果:相比于单独用药组和单独放疗组,联合组能够显著抑制肿瘤体积生长,延长荷瘤裸鼠的中位生存期。结论:替吉奥单独给药和单独三维适形放疗均能抑制肿瘤的生长,二者联合使用能够发挥协同作用,是一种潜在的高效的胰腺癌治疗手段。 Objective: To estimate the effect of S-1 combined with three-dimensional conformal radiotherapy on the biological be- haviour of pancreatic cancer cells. Methods: PANC-1 cells were cultured and xenografted in athymic nude mice to establish the animal model, which were used to evaluate the effect of anti-pancreatic cancer. In addition, we evaluated the side effect of the combined treat- ment. Results: The combination of S-1 and three-dimensional conformal radiotherapy can prolong the median survival time of PANC-1 bearing nude mice than other groups significantly. Conclusion: The combination of S-1 and three-dimensional conformal radiotherapy may be a potentially effective treatment for pancreatic cancer with the advantages of inhibiting the growth of pancreatic cancer.
出处 《现代生物医学进展》 CAS 2013年第34期6650-6652,共3页 Progress in Modern Biomedicine
基金 国家自然科学基金项目(81071693)
关键词 替吉奥 三维适形放疗 胰腺癌 S-1 Three-dimensional conformal radiotherapy Pancreatic cancer
  • 相关文献

参考文献19

  • 1Blackstock AW, Momex F, C, et al. Adjuvant gemcitabine and concur- rent radiation for patients with resected pancreatic cancer a phase II study[J]. Br J Cancer, 2006, 95:260-265.
  • 2Vincent A, Herman J, Schulick R, et al. Pancreatic cancer [J]. Lancet, 2011,378:607-620.
  • 3Sudo K, Yamaguchi T, Ishihara T, et al. Phase II study of oral S-1 and concurrent radiotherapy in patients with unrcsectable locally ad- vanced pancreatic cancer [J]. Int J Radiat Oncol Bio! Phys, 2011,80: 119-125.
  • 4Peters GJ, Noordhuis P, Van Kuilenburg AB, et al. Pharmacokinetics of S-1,an oral formulation of ftorafur,oxonic acid and 5-chloro-2,4-di- hydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors[J]. Cancer Chemother Pharmacol, 2003,52:1-12.
  • 5Sudo K, Yamaguchi T, Nakamura K, et al. Phase II study of S-1 in pa- tients with gemcitabine-resistant advanced pancreatic cancer[J]. Can- cer Chemother Pharmacol,2011,67:249-254.
  • 6Shinchi H, Maemura K, Mataki Y, et al. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer [J]. J Hepatobiliary Pan- creat Sci, 2011,6:7.
  • 7Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-time therapy for patients with advanced pancreas cancer: arandomized trial [J]. ClinOncol, 1997,15(6): 2403-2413.
  • 8DasP, Wolff RA. Concurrent capecitabine and upper abdominal radia- tion therapy is well to lerated[J]. Radial Oneol,2006, 1:41.
  • 9Muro K, Boku N, Shimada Y, et al. Irinotecan plus S -1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second -line chemotherapy for metastatic colorectal cancer: a randomized phase 2 /3 non-inferiority study (FIRIS study)[J]. Lancet Oncol, 2010,9: 853-860.
  • 10Chang, Y. Therapeutic efficacy and microSPECT/CT imaging of Re-188-DXR-liposome in a C26 murine colon carcinoma solid tumor model [J]. Nucl. Med. Biol, 2010, 37:95-104.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部